Growth hormone peptides reddit

Reddit's growth hormone peptide communities cluster around five core compounds: Ipamorelin, CJC-1295 DAC, MK-677, Sermorelin, and Tesamorelin. What makes these discussions valuable is not consensus — there is none — but the collision between anecdote, published dosing protocols, and the gaps neither side acknowledges. The most upvoted posts often cite rodent half-lives while ignoring route-dependent bioavailability; the most downvoted posts are frequently the only ones that mention blinding.

What Separates Growth Hormone Secretagogues from Direct GH Administration

Growth hormone peptides function through two distinct mechanisms. Growth hormone-releasing hormone (GHRH) analogs — CJC-1295 DAC, Sermorelin, Tesamorelin, and Mod GRF 1-29 — bind to GHRH receptors on anterior pituitary somatotrophs, triggering endogenous pulsatile GH release. Growth hormone-releasing peptides (GHRPs) — Ipamorelin, GHRP-2, GHRP-6, and Hexarelin — bind to the ghrelin receptor (GHS-R1a), stimulating GH secretion through a pathway independent of GHRH. MK-677 occupies a hybrid position: it is not a peptide but a small-molecule ghrelin mimetic, orally bioavailable, with a 24-hour half-life that produces sustained rather than pulsatile secretion.

The structural differences matter for practical use. CJC-1295 with DAC (Drug Affinity Complex) extends half-life from minutes to approximately 6-8 days through albumin binding, converting a short-acting GHRH analog into a long-acting depot formulation. The non-DAC version, marketed as Mod GRF 1-29, retains the ~30-minute half-life of native GHRH. Ipamorelin's selectivity for GH release without significant cortisol or prolactin elevation distinguishes it from earlier GHRPs like GHRP-6, which stimulate appetite through ghrelin pathway activation. Reddit discussions frequently miss this: "stack CJC with Ipam" recommendations rarely specify whether the CJC is DAC or non-DAC, which fundamentally alters dosing frequency.

Tesamorelin differs from other GHRH analogs in one FDA-approved clinical context: HIV-associated lipodystrophy. It received approval in 2010 based on two Phase III trials showing visceral adipose tissue reduction of 15-18% at 2 mg/day subcutaneous dosing over 26 weeks. This makes it the only growth hormone secretagogue with regulatory backing for a metabolic indication, though Reddit interest centers on off-label body composition use.

How GHRH and GHRP Pathways Converge on Somatotroph Cells

GHRH binds to a G-protein coupled receptor (GPCR) on pituitary somatotrophs, activating adenylyl cyclase and raising intracellular cAMP. This triggers protein kinase A (PKA) signaling, which phosphorylates transcription factors that increase GH gene transcription and also mobilizes stored GH granules for immediate release. The effect is pulsatile — a sharp rise in serum GH peaking 30-60 minutes post-injection, followed by return to baseline within 2-3 hours for natural GHRH or short-acting analogs.

GHRPs bind GHS-R1a, a GPCR that activates phospholipase C (PLC), increasing intracellular calcium and triggering GH granule exocytosis through a calcium-dependent pathway. Critically, GHS-R1a activation also inhibits somatostatin release from hypothalamic neurons, removing the tonic brake on somatotroph activity. This dual mechanism — direct stimulation plus disinhibition — explains why GHRPs produce larger GH pulses than GHRH analogs at equipotent doses in rodent models.

The synergy between GHRH and GHRP pathways is not additive but multiplicative. In a 1997 study by Bowers et al. using rhesus monkeys, GHRP-2 alone raised GH 3-fold; GHRH alone raised it 4-fold; the combination raised it 12-fold. This synergy persists in human pharmacokinetic studies. A 2005 trial in healthy men showed that 1 mcg/kg GHRP-2 plus 1 mcg/kg GHRH produced a GH pulse 8-fold higher than either agent alone. Reddit protocols that "stack" a GHRP with a GHRH analog are following this published synergy, though the dosing ratios cited (often "100 mcg each") rarely map to the weight-adjusted doses used in controlled trials.

MK-677 operates through GHS-R1a like peptide GHRPs but with critical pharmacokinetic differences. Its 24-hour half-life produces sustained receptor occupancy, which shifts GH secretion from pulsatile to continuous elevation. A 1997 study by Chapman et al. showed that 25 mg daily MK-677 raised mean 24-hour GH by 97% in healthy young men, but peak GH was only 30% higher than baseline — the increase came from elevated troughs. Whether sustained elevation offers the same downstream benefits as pulsatile secretion is unresolved; IGF-1 rises were comparable, but lean mass outcomes in 12-month trials showed high inter-subject variability.

What Controlled Trials Show for Body Composition and What They Don't

Sermorelin's longest controlled trial remains a 16-week study in 26 healthy men over age 60 (Khorram et al., 1997). Subjects received 10 mcg/kg subcutaneously at bedtime, which raised mean 24-hour GH by ~75%. Lean mass increased by 1.2 kg (vs. 0.3 kg placebo); fat mass decreased by 0.9 kg (vs. 0.2 kg placebo). No change in strength or VO2max. The study was not powered for performance outcomes. Follow-up longer than 16 weeks does not exist in published form for Sermorelin in non-deficient adults.

Tesamorelin's two pivotal trials (Stanley et al., 2010; Falutz et al., 2010) enrolled 816 HIV-positive adults with visceral adiposity. The 2 mg/day dose reduced visceral adipose tissue (VAT) by 15.2% at 26 weeks vs. 4.9% placebo, measured by CT at L4-L5. Subcutaneous fat did not change. Lean mass increased by ~1 kg. IGF-1 rose into the upper-normal range but normalized after discontinuation. Adverse events included injection site reactions (30%) and mild hyperglycemia (6%). Notably, VAT reduction reversed within 6 months of stopping treatment, suggesting that ongoing use is required to maintain effects. Reddit discussions citing "permanent fat loss" from Tesamorelin are not supported by these re-accumulation data.

MK-677's longest trial is a 12-month study in 65 healthy older adults by Nass et al. (2008). The 25 mg daily dose raised IGF-1 by ~60% and maintained that elevation throughout the year. Lean mass increased by 1.1 kg at 12 months (vs. 0.2 kg placebo); fat mass increased by 1.3 kg (vs. 0.3 kg placebo). The simultaneous increase in lean and fat mass distinguishes MK-677 from direct GH administration, which typically reduces fat. Appetite stimulation was reported by 40% of subjects. Fasting glucose rose by 5-7 mg/dL; HbA1c did not change. One case of mild carpal tunnel syndrome occurred. The trial excluded anyone with baseline fasting glucose over 110 mg/dL, so glycemic effects in prediabetic individuals remain uncharacterized.

Ipamorelin has no published human trials longer than 2 weeks. A Phase II study in growth hormone deficiency (Andersen et al., 2001) used 0.5, 1.0, and 1.5 mcg/kg subcutaneously twice daily for 15 days. The 1.5 mcg/kg dose raised 24-hour GH AUC by ~80% with no cortisol or prolactin elevation. The trial ended at Day 15. No data exist on Ipamorelin's effects on body composition, strength, or metabolic markers beyond acute GH secretion. Reddit protocols citing multi-month Ipamorelin use are extrapolating from absence.

CJC-1295 DAC has one published human trial: a Phase I study by Teichman et al. (2006) in 47 healthy adults. Single doses of 30, 60, 90, and 120 mcg/kg raised IGF-1 by 30-60% and sustained elevation for 7-14 days depending on dose. Mean GH increased 2- to 3-fold. The trial was a safety/PK study; it measured no body composition outcomes. A follow-up efficacy trial has never been published, though it was listed on ClinicalTrials.gov in 2008 and marked "terminated" in 2010 with no results posted.

For research purposes only, the gap between published dosing and Reddit protocols is instructive. Published trials used weight-adjusted dosing (mcg/kg); Reddit protocols universally use fixed doses (100-300 mcg). A 100 mcg dose of Ipamorelin in a 90 kg individual is 1.1 mcg/kg — within the Phase II range. The same dose in a 70 kg individual is 1.4 mcg/kg. The same dose in a 110 kg individual is 0.9 mcg/kg. Whether this variation matters depends on whether dose-response is linear in this range, which has not been characterized in published human studies beyond the single-dose Andersen trial.

Dose Ranges, Administration Routes, and Half-Life Data from Published Literature

Sermorelin's published human dosing: 0.3-10 mcg/kg subcutaneously at bedtime. The bedtime timing capitalizes on the nocturnal GH pulse; Sermorelin's 8-minute half-life means it clears before the second pulse 3-4 hours later. Daily administration mimics endogenous pulsatility.

Tesamorelin's FDA-approved dose: 2 mg subcutaneously once daily, abdominal injection. No weight adjustment. Half-life is ~26 minutes. The dose was not titrated in pivotal trials — 2 mg was chosen based on Phase II dose-ranging that tested 0.5, 1.0, 1.4, and 2.0 mg, with 2.0 mg showing superior VAT reduction.

Ipamorelin's Phase II dose: 0.5-1.5 mcg/kg subcutaneously, 2-3 times daily. The 2- to 4-hour half-life requires multiple doses to sustain GH elevation. Reddit protocols using once-daily Ipamorelin are not following the published PK; the compound clears within 8 hours.

CJC-1295 DAC's Phase I dose: 30-120 mcg/kg subcutaneously, once every 7-14 days. The DAC modification extends half-life to ~6-8 days through albumin binding, converting it into a depot formulation. Reddit discussions of "daily CJC injections" often conflate CJC-1295 DAC with Mod GRF 1-29 (non-DAC CJC), which has a 30-minute half-life and requires 1-3 daily doses.

MK-677's clinical dose: 10-25 mg orally once daily. The 24-hour half-life means steady-state is reached after 4-5 days. Studies used evening dosing to align with nocturnal GH secretion, though PK modeling suggests timing matters less at steady-state. Higher doses (50 mg) did not produce proportionally greater IGF-1 increases in the Chapman trial, suggesting a ceiling effect.

Reconstitution and stability: GHRH and GHRP peptides are supplied lyophilized and reconstituted with bacteriostatic water. Reconstituted Sermorelin and Ipamorelin are stable for 2-4 weeks refrigerated based on manufacturer data; no peer-reviewed stability studies exist. CJC-1295 DAC's albumin-binding mechanism may reduce refrigeration sensitivity, but published degradation curves are absent. MK-677 is orally bioavailable and does not require reconstitution.

Notable pharmacokinetic interactions: GHRH analogs and GHRPs act synergistically, as noted earlier. Concurrent use of exogenous testosterone or other androgens may increase IGF-1 response to GH secretagogues, based on a 2001 study by Veldhuis et al. showing that testosterone amplifies GH's effects on IGF-1 production in hypogonadal men. Conversely, high-dose glucocorticoids blunt GH secretion through hypothalamic suppression; a 2004 study showed that dexamethasone reduced GH response to GHRP-6 by ~50% in healthy volunteers. Metformin's effects on GH secretagogue efficacy are unclear; one uncontrolled 2019 observational study suggested metformin users had lower IGF-1 responses to MK-677, but confounding by indication (type 2 diabetes) makes interpretation difficult.

Reddit's Most Common Dosing Errors and the Evidence They Ignore

The "100 mcg Ipamorelin + 100 mcg CJC-1295" stack appears in dozens of Reddit threads, often cited as a "standard research dose." This pairing conflates evidence from different studies that used weight-adjusted dosing and specified whether CJC was DAC or non-DAC. If the CJC is DAC and dosed at 100 mcg, a 90 kg individual receives 1.1 mcg/kg — below the 30 mcg/kg minimum tested in the Teichman Phase I trial. If the CJC is Mod GRF 1-29 (non-DAC), 100 mcg may approximate published ranges, but the dosing frequency (once daily vs. three times daily) changes the cumulative exposure substantially. Ipamorelin at 100 mcg in a 90 kg person is 1.1 mcg/kg, within the 0.5-1.5 mcg/kg Phase II range, but the twice-daily dosing from that trial is rarely mentioned.

Another common claim: "MK-677 is safer than peptides because it's oral." This confuses administration route with safety profile. MK-677's sustained GH elevation produced fasting glucose increases of 5-7 mg/dL in the Nass 12-month trial, a magnitude not seen with pulsatile secretagogues in short trials. Whether this reflects a mechanistic difference (sustained vs. pulsatile) or simply longer observation (12 months vs. 16 weeks) is unresolved. The oral route eliminates injection site reactions but introduces first-pass hepatic metabolism, which is why bioavailability is ~60% and dose-proportionality is nonlinear above 25 mg.

A third pattern: equating Tesamorelin's VAT reduction in HIV lipodystrophy with fat loss in non-lipodystrophic individuals. The 15% VAT reduction in the Stanley and Falutz trials occurred in a population with pathological visceral fat accumulation driven by antiretroviral therapy. Whether the same magnitude occurs in individuals with normal-range visceral fat is untested. A 2015 pilot study in obese non-HIV adults (Makimura et al.) showed 6.1% VAT reduction after 26 weeks at the same 2 mg dose — less than half the effect size seen in lipodystrophy. Reddit discussions citing "15% fat loss" without specifying the baseline population overstate the generalizability.

FAQ

Q: Which growth hormone peptide has the longest human trial data?

MK-677 has the longest published controlled trial: 12 months in 65 healthy older adults (Nass et al., 2008). Tesamorelin has two 26-week trials in HIV lipodystrophy. Sermorelin's longest trial is 16 weeks. Ipamorelin has no trials beyond 15 days. CJC-1295 DAC has single-dose PK data only — no chronic administration study has been published.

Q: Do you need to cycle growth hormone peptides, and what evidence supports cycling?

No published human trial has tested cycling protocols. The concept of "desensitization" appears in Reddit discussions without citation to receptor downregulation data. MK-677's 12-month trial showed sustained IGF-1 elevation without attenuation, suggesting GHS-R1a does not desensitize over that timeframe. GHRH receptor downregulation occurs in cell culture models with continuous agonist exposure, but whether this translates to clinically meaningful attenuation with pulsatile human dosing is unknown.

Q: Is CJC-1295 "with DAC" the same as Mod GRF 1-29?

No. CJC-1295 with DAC is the albumin-binding version with a 6-8 day half-life, dosed weekly or biweekly. Mod GRF 1-29 is CJC-1295 without the DAC modification, giving it a 30-minute half-life identical to native GHRH. They require different dosing frequencies. Reddit posts that say "CJC" without specifying DAC status are describing different compounds.

Q: Does Ipamorelin's selectivity mean it has fewer side effects than GHRP-6?

In the 15-day Phase II trial, Ipamorelin did not raise cortisol or prolactin, while GHRP-6 raised both in earlier studies. Whether this translates to fewer long-term side effects is speculation — no head-to-head trial has compared them beyond 2 weeks. Appetite stimulation was lower with Ipamorelin, which follows from its lack of ghrelin-pathway hunger signaling. Injection site reactions occurred at similar rates.

Q: Can you use Sermorelin and MK-677 together?

Mechanistically, yes — Sermorelin acts through GHRH receptors and MK-677 through GHS-R1a, so their pathways are non-redundant. No published trial has tested this combination. The Nass MK-677 trial showed that sustained elevation increases lean mass with some fat gain; Sermorelin trials showed lean mass gain without fat gain. Whether combining them produces additive, synergistic, or interfering effects on body composition is uncharacterized in human data.

Medical Disclaimer: The information provided here is for educational and research purposes only. Growth hormone peptides are not approved for body composition, anti-aging, or performance enhancement in healthy adults. Use of these compounds outside supervised clinical trials or approved indications carries uncharacterized risks. Consult a licensed healthcare provider before considering any peptide therapy.